 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Cortexyme, Inc. Nasdaq: CRTX, a company advancing a pivotal trial in Alzheimers disease on schedule to be announced in Q4 2021 and a pipeline of therapeutics for degenerative diseases, today announced a series of leadership appointments to support the continued advancement and commercial planning of atuzaginstat, as well as the companys pipeline expansion and regulatory affairs capabilities. Expanding Cortexymes leadership team strengthens our 